Nancy Lane, MD
Rheumatology · Sacramento, CANPI 1467435321
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Amgen at 47.8% of the total. Reporting peaked in 2019 at $109,169 and has fallen 65.0% since, to $38,232 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $879.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$133K
- Ipsen Biopharmaceuticals, Inc$17K
- Mallinckrodt Hospital Products Inc.$15K
- GSK$12K
- Mallinckrodt Enterprises LLC$11K
- Eli Lilly$11K
- plus $79K from 26 others
Across 36 payments — averaging $3005.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$39K
- Regeneron$34K
- AbbVie$22K
- ANI Pharmaceuticals, Inc.$6K
- Amgen$4K
- Radius Health, Inc.$3K
What the payments were for
- Consulting fees$118,31543%
- Speaking & faculty fees$121,82244%
- Travel & lodging$32,30612%
- Food & beverage$5,5852%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 195 | $132,913 |
| Ipsen Biopharmaceuticals, Inc | 9 | $17,027 |
| Mallinckrodt Hospital Products Inc. | 7 | $14,833 |
| GSK | 9 | $12,443 |
| Mallinckrodt Enterprises LLC | 15 | $11,167 |
| Eli Lilly | 4 | $10,675 |
| Pacira Pharmaceuticals Incorporated | 3 | $8,843 |
| Pfizer | 4 | $8,267 |
| Ultragenyx Pharmaceutical Inc. | 4 | $7,223 |
| Kyowa Kirin, Inc. | 11 | $6,927 |
| AbbVie | 9 | $6,105 |
| Merck | 3 | $5,871 |
| Noven Therapeutics, LLC | 5 | $5,832 |
| Gilead | 2 | $4,767 |
| Lilly USA, LLC | 3 | $4,278 |
| Boehringer Ingelheim | 3 | $3,975 |
| UCB, Inc. | 4 | $3,562 |
| Novo Nordisk | 2 | $3,000 |
| ANI Pharmaceuticals, Inc. | 2 | $2,628 |
| Novo Nordisk AS | 1 | $1,688 |
| Noven Pharmaceuticals, Inc. | 2 | $1,500 |
| Organon | 2 | $1,300 |
| Kowa Pharmaceuticals America, Inc. | 1 | $900 |
| Johnson & Johnson | 1 | $750 |
| AstraZeneca | 2 | $632 |
| Amneal Pharmaceuticals LLC | 1 | $233 |
| Aurinia Pharma U.S., Inc. | 5 | $162 |
| Radius Health, Inc. | 3 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $130 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Regeneron | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$278,027 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 18 | $111,288 |
| Alendronate Sodium | 28 | $251 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Sacramento
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.